CaroGen Corp, a developer of immunotherapies for HBV as well as other infectious diseases and cancer, announced today additions to its Board of Directors and named two key senior executive level scientists to its immunotherapy discovery and development team.

Bijan Almassian, Ph.D., CaroGen’s CEO, said, “The addition of these three impressive and experienced individuals, greatly  strengthens the CaroGen team and positions the company well with respect to executing on its immunotherapy plans”.​